Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

886 - Novel drug discovery for cancer invasion and metastasis


24 Nov 2018


Poster display - Cocktail


Clinical Research

Tumour Site

Colon and Rectal Cancer


Hwi Jung Na


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


H.J. Na1, S.Y. Park1, S.J. Lee2, Y.R. Kim3, J.W. Choi4

Author affiliations

  • 1 Research Institute, ONCOCROSS, 04168 - Seoul/KR
  • 2 Research Institute, ONCOCROSS, Seoul/KR
  • 3 Hemato-oncology, Sun Medical Center, 34811 - Daejeon/KR
  • 4 Department Of Pharmacology, Kyung Hee University, Seoul/KR


Abstract 886


Cancer recurrence and metastasis are life threatening condition to cancer patients. Although adjuvant chemotherapy is used to prevent recurrence, the preventive effects are unsatisfactory and cancer patients suffer from several side effects. There is a need for drugs have higher cancer prevention effects but lower side effects.


In silico assay, which can facilitate the rate of the appropriate drug discovery for specific disease by computer simulation, has been rapidly developing. As using in silico assay, we discovered OC-201 by comparing differences of gene expression patterns between colon adenoma and colon carcinoma, between poor prognosis colon cancer patients and good prognosis colon cancer patients. Also, OC-202, which is complementary role to OC-201, was also discovered. Anti-invasion and anti-metastasis effect of both OC-201 and OC-202 drugs have been evaluated in colon cancer, biliary cancer and pancreatic cancer in vitro and in vivo.


At non-toxic concentrations in colon cancer cells, OC-201 and OC-202 suppressed colon cancer cells invasion and migration, which is a crucial mechanism associated with cancer metastasis. Co-treatment of OC-201 and OC-202 showed synergic anti-invasion and anti-migration effect compared to alone. In addition, OC-201 and OC-202 also suppressed colony formation by soft agar assay which is the method measured anchorage independent growth. These drugs regulated that epithelial to mesenchymal transition markers such as vimentin and N-cadherin. In vivo experiments, OC-201 and OC-202 decreased number of lung metastasis up to 70% in mouse colon cancer xenograft model. Intriguingly, OC-201 and OC-202 showed same results in biliary cancer and pancreas cancer cell lines. OC-201 and OC-202 co-treatment is more effective than alone in all data and cancer types.


OC-201 and OC-202 could be potent metastasis inhibitors via blocking cancer cell invasion and migration by regulating EMT.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study



Has not received any funding.


H.J. Na, S.Y. Park, S.J. Lee: Employee: Oncocross which is a pharmaceutical company. Y.R. Kim: CEO: Oncocross which is a pharmaceutical company. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.